N.F.U. MUTUAL UNIT MANAGERS Ltd Makes New $5.10 Million Investment in Eli Lilly and Company $LLY

N.F.U. MUTUAL UNIT MANAGERS Ltd bought a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 4,395 shares of the company’s stock, valued at approximately $5,099,000. Eli Lilly and Company accounts for approximately 0.9% of N.F.U. MUTUAL UNIT MANAGERS Ltd’s investment portfolio, making the stock its 22nd biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Portland Global Advisors LLC grew its stake in Eli Lilly and Company by 63.8% during the third quarter. Portland Global Advisors LLC now owns 1,451 shares of the company’s stock worth $1,679,000 after buying an additional 565 shares during the last quarter. Disciplined Investors L.L.C. increased its holdings in shares of Eli Lilly and Company by 43.0% during the third quarter. Disciplined Investors L.L.C. now owns 791 shares of the company’s stock worth $915,000 after buying an additional 238 shares in the last quarter. Cvfg LLC raised its stake in shares of Eli Lilly and Company by 4.3% in the third quarter. Cvfg LLC now owns 17,038 shares of the company’s stock valued at $19,714,000 after acquiring an additional 701 shares during the last quarter. Bouchey Financial Group Ltd. raised its stake in shares of Eli Lilly and Company by 2.0% in the third quarter. Bouchey Financial Group Ltd. now owns 1,207 shares of the company’s stock valued at $1,397,000 after acquiring an additional 24 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its stake in shares of Eli Lilly and Company by 9.4% in the third quarter. Meeder Advisory Services Inc. now owns 22,290 shares of the company’s stock valued at $25,791,000 after acquiring an additional 1,923 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Citigroup raised their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a report on Friday, October 30th. Bank of America reiterated a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,422.00.

Read Our Latest Research Report on LLY

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,346.40 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a market cap of $1.27 trillion, a P/E ratio of 43.70, a P/E/G ratio of 1.61 and a beta of 0.40. The firm has a 50 day simple moving average of $1,268.06 and a 200 day simple moving average of $1,119.25. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 EPS. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 35.73 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Recent Eli Lilly and Company Headlines

These are some of the LLY headlines that stood out recently:

  • Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
  • Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
  • Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.